CytomX Therapeutics, Inc.

CTMX Nasdaq SEC CIK 1501989
Follow CytomX Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.7M −71.7% vs same quarter last year
Net income −$20M −40.5% vs same quarter last year
EPS, diluted -
Operating cash flow $16.6M +207.1% vs same quarter last year
Revenue by quarter
$38.1M
$50.9M
$18.7M
$6M
$663K
$10.3M
$1.4M
$1.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$76.2M−$17.4M
FY24$138.1M$31.9M
FY23$101.2M−$569K
FY22$53.2M−$99.3M
FY21$37.3M−$115.9M
FY20$68.4M−$64.8M
FY19$26.9M−$132.8M
FY18$59.5M−$84.6M
FY17$71.6M−$43.1M
FY16$12.8M−$58.9M
FY15$7.7M−$35.4M
FY14$5.1M−$30.3M
FY13$888K−$15.1M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−29.3%−22.8%
FY2418.1%23.1%
FY23−6.4%−0.6%
FY22−190.6%−186.8%
FY21−311%−310.5%
FY20−117.7%−94.7%
FY19−525.9%−493.7%
FY18−130.9%−142.2%
FY17−64.6%−60.2%
FY16−463.9%−458.5%
FY15−430.5%−458.7%
FY14−586.3%−597%
FY13−1684.2%−1705.3%
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$75.8M
FY24−$86.5M
FY23−$56.9M
FY22−$112.5M
FY21−$120.6M
FY20$3M
FY19−$144M
FY18−$79.3M
FY17$168.8M
FY16−$4.2M
FY15−$29M
FY14$30.1M
FY13−$8.7M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • CytomX Therapeutics
  • Healthcare median
−2000%−1500%−1000%−500%0%500%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCytomX TherapeuticsHealthcare median
FY25−22.8%−30.6%
FY2423.1%−47%
FY23−0.6%−58%
FY22−186.8%−80.4%
FY21−310.5%−71.8%
FY20−94.7%−62.2%
FY19−493.7%−46.2%
FY18−142.2%−49.6%
FY17−60.2%−45.9%
FY16−458.5%−36%
FY15−458.7%−37.8%
FY14−597%−35.5%
FY13−1705.3%−37.1%
FY12-−29.1%